Evidence map›Paper›PMID 29400320›Full record

ArticleActa crystallographica. Section F, Structural biology communications2018

Structural characterization of Porphyromonas gingivalis enoyl-ACP reductase II (FabK).

Kirk E Hevener, Bernard D Santarsiero, Hyun Lee, Jesse A Jones, Teuta Boci, Michael E Johnson, Shahila Mehboob

Open access · greenAbstract read
In one paragraph

Article in Acta crystallographica. Section F, Structural biology communications, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Mining Fatty Acid Biosynthesis for New Antimicrobials.Annual review of microbiology · 2022
    Review
  6. Review
  7. Article
  8. Small-Molecule Inhibition of theACS chemical biology · 2019
    Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Kirk E HevenerDepartment of Pharmaceutical Sciences, University of Tennessee Health Science Center, 881 Madison Avenue, Suite 571, Memphis, TN 38163-2198, USA.ORCID 0000-0002-5584-3625
Bernard D SantarsieroCenter for Pharmaceutical Biotechnology, University of Illinois at Chicago, 900 South Ashland Avenue, Suite 3100, Chicago, IL 60607-7173, USA.
Hyun LeeCenter for Pharmaceutical Biotechnology, University of Illinois at Chicago, 900 South Ashland Avenue, Suite 3100, Chicago, IL 60607-7173, USA.
Jesse A JonesDepartment of Pharmaceutical Sciences, University of Tennessee Health Science Center, 881 Madison Avenue, Suite 571, Memphis, TN 38163-2198, USA.ORCID 0000-0001-8006-5661
Teuta BociCenter for Pharmaceutical Biotechnology, University of Illinois at Chicago, 900 South Ashland Avenue, Suite 3100, Chicago, IL 60607-7173, USA.
Michael E JohnsonCenter for Pharmaceutical Biotechnology, University of Illinois at Chicago, 900 South Ashland Avenue, Suite 3100, Chicago, IL 60607-7173, USA.
Shahila MehboobCenter for Pharmaceutical Biotechnology, University of Illinois at Chicago, 900 South Ashland Avenue, Suite 3100, Chicago, IL 60607-7173, USA.
University of Illinois Chicago · USUniversity of Tennessee Health Science Center · US

Funding

Multidisciplinary Oral Science TrainingT32DE018381 · NIDCR · UNIVERSITY OF ILLINOIS AT CHICAGO · PI COOPER, LYNDON F · 2008 to 2019
$3.6M
Investigation of the FAS-II enzyme, FabK, as a druggable target for C. difficileR21AI126755 · NIAID · UNIVERSITY OF TENNESSEE HEALTH SCI CTR · PI HEVENER, KIRK EDWARD, HURDLE, JULIAN G · 2016 to 2017
$424k
Michigan Economic Development Corporation 085P1000817NIAID NIH HHS R21 AI126755NIDCR NIH HHS 5T32-DE018381NIDCR NIH HHS T32 DE018381US Department of Energy, Office of Science DE-AC02-11357
6 · The paper itself

Abstract

Enoyl-acyl carrier protein (ACP) reductase II (FabK) is a critical rate-limiting enzyme in the bacterial type II fatty-acid synthesis (FAS II) pathway. FAS II pathway enzymes are markedly disparate from their mammalian analogs in the FAS I pathway in both structure and mechanism. Enzymes involved in bacterial fatty-acid synthesis represent viable drug targets for Gram-negative pathogens, and historical precedent exists for targeting them in the treatment of diseases of the oral cavity. The Gram-negative organism Porphyromonas gingivalis represents a key causative agent of the costly and highly prevalent disease known as chronic periodontitis, and exclusively expresses FabK as its enoyl reductase enzyme in the FAS-II pathway. Together, these characteristics distinguish P. gingivalis FabK (PgFabK) as an attractive and novel narrow-spectrum antibacterial target candidate. PgFabK is a flavoenzyme that is dependent on FMN and NADPH as cofactors for the enzymatic reaction, which reduces the enoyl substrate via a ping-pong mechanism. Here, the structure of the PgFabK enzyme as determined using X-ray crystallography is reported to 1.9 Å resolution with endogenous FMN fully resolved and the NADPH cofactor partially resolved. PgFabK possesses a TIM-barrel motif, and all flexible loops are visible. The determined structure has allowed insight into the structural basis for the NADPH dependence observed in PgFabK and the role of a monovalent cation that has been observed in previous studies to be stringently required for FabK activity. The PgFabK structure and the insights gleaned from its analysis will facilitate structure-based drug-discovery efforts towards the prevention and treatment of P. gingivalis infection.

Indexed as

Amino Acid SequenceCell LineEnoyl-(Acyl-Carrier-Protein) Reductase (NADH)HumansPorphyromonas gingivalisProtein Structure, SecondaryX-Ray DiffractionEnoyl-(Acyl-Carrier-Protein) Reductase (NADH)crystal structureenoyl-ACP reductase IIFabKperiodontal diseasePorphyromonas gingivalis

Identifiers

PMID29400320
PMCPMC5947681
OpenAlexW2793910399

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.